Global Torsemide Market Size, Share and Trends Analysis Report, By Dosage Form (Tablets, and Injection), By Application (Cardiovascular Diseases, Kidney Diseases, Liver Diseases, and Others), By Distribution Channel (Hospital Pharmacies, and Retail Drug Stores), Forecast (2022-2028)

The global Torsemide market is anticipated to grow at a considerable CAGR 2% during the forecast period (2022-2028). Torsemide, also called Torasemide is a diuretic drug used for the treatment of patients with cardiovascular disease, kidney diseases, and liver diseases. The major factor attributing to the growth of the global torsemide market is the increasing prevalence of kidney diseases across the globe. According to the National Kidney Foundation, around 37 million people are affected by kidney diseases in the US alone. Around 80 million adults in the US are expected to have the risk of developing kidney diseases, representing one in every three adults in the US. Chronic Kidney Disease (CKD) is estimated to have more mortality rate than breast or prostate cancer.

In Addition, the increasing prevalence of liver diseases and cardiovascular diseases across the globe is also increasing the demand for torsemide for reducing the risks associated with liver diseases and cardiovascular diseases. According to a report published by World Health Organisation (WHO) in June 2021, cardiovascular diseases are one of the leading causes of mortality across the globe. In 2019, the mortality due to cardiovascular diseases is estimated to be around 17.9 million, representing 32% of the global mortality number. Among these, 85% of mortality is due to heart failure. Furthermore, according to the Centers for Disease Control and Prevention (CDC), around 4.5 million adults are diagnosed with liver diseases in the US alone representing 1.8% of the total adult population of the US. The recorded mortality due to liver diseases is around 51,642 in the US. The diseases are increasing due to several reasons including increased consumption of alcohol, smoking, bad eating habits, changing living styles, and hypertension, among others.

The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, Sarfez Pharmaceuticals got approval from the US Food and Drug Administration (FDA) of New Drug Application (NDA) for Soaanz. Soaanz is a once-a-day loop diuretic torsemide drug that can be taken in oral form for the treatment of symptoms including edema, swelling in lower limb or abdomen in patients with heart failure.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Dosage Form
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Cayman Pharma s.r.o, LGC Ltd., BOC Sciences Inc., Globus Remedies Ltd., and Sun Pharmaceuticals Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Torsemide  Market Report by Segment

By Dosage Form

• Tablets
• Injection

By Application

• Cardiovascular Diseases
• Kidney Diseases
• Liver Diseases

By Distribution Channel

• Hospital Pharmacies
• Retail Drug Stores

Global Torsemide  Market Report by Region

North America

• The United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa